Oncotrail RGCC provides crucial information on the presence of circulating tumour cells (CTCs) and their concentration in patients who have a confirmed diagnosis of specific forms of cancer, including breast, colon and prostate cancer.
During the test, a sample of blood is analysed to identify the presence and concentration of CTC and their immunophenotype.
Oncotrail RGCC isn’t used as a primary diagnostic test to confirm a cancer diagnosis, but provides essential information on the effectiveness of current cancer treatments. Follow-up tests can also be used to monitor a patient’s health and assess the risk of relapse.
Test details
Sample type
Whole peripheral blood sample
Analysis period
Approx. 7 days
Cancer type
Breast, Colon, GI, Lung, Melanoma, Prostate and Sarcoma
Final results
7-10 days after sample delivery
Sample size
10-15 ml peripheral whole blood
Price*
775 €
* The prices of the tests may be an issue of local additional taxes and value added taxes which are dependent of each country’s legislation. The prices may vary in areas that are under the jurisdiction of a distributor. These prices are for the tests only, and they do not include in-office fees such as consultation, blood draws, etc.
* RGCC is not liable for any third-party comments or claims regarding our products. For accurate and up-to-date information about our offerings, please refer to our official website: rgcc-international.com
